| Dr Farzad Saleh, DPM | |
|
6130 Oxon Hill Rd Ste 305, Oxon Hill, MD 20745-3168 | |
| (301) 567-5005 | |
| (301) 839-5677 |
| Full Name | Dr Farzad Saleh |
|---|---|
| Gender | Male |
| Speciality | Podiatry |
| Experience | 8 Years |
| Location | 6130 Oxon Hill Rd Ste 305, Oxon Hill, Maryland |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073962270 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Progressive Feet Llc | 1951660042 | 10 |
| Progressive Feet Llc | 1951660042 | 10 |
News Archive
Zalicus Inc. today announced the publication of preclinical data in the journal PAIN. The paper describes the activity of Z212, a novel proprietary small organic compound that acts to modulate Nav1.7 and Nav1.8 sodium channels and to reduce neuropathic pain by targeting the hyper-excitability associated with chronic pain signaling pathways.
More than half of all retired people aged 65 and over report sleeping at least 7.5 hours per night, and between the hours of 11 p.m. and 7:30 a.m., contrary to commonly held assumptions that most elderly go to bed early and have trouble sleeping through the night, according to a study by researchers at the University of Pittsburgh's Sleep and Chronobiology Center (SCC) and University Center for Social and Urban Research (UCSUR).
Merck, known as MSD outside the United States and Canada, and BGI, the world's largest genomics center, announced today that they have established a collaboration to focus on the discovery and development of biomarkers and genomic technologies.
ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announces that the US Food and Drug Administration (FDA) has notified the Company that its new biologic license application (BLA) for ocriplasmin intravitreal injection will be discussed at the Dermatologic and Ophthalmic Drugs Advisory Committee scheduled for July 26, 2012.
A study published in the journal "Cytogenetic and Genome Research" shows that exposure to Agent Orange, and other defoliants, has led to genetic disturbance in New Zealand Vietnam War veterans which continues to persist decades after their service.
› Verified 5 days ago
| Provider Name | Progressive Feet Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1609380989 PECOS PAC ID: 1951660042 Enrollment ID: O20180118000452 |
News Archive
Zalicus Inc. today announced the publication of preclinical data in the journal PAIN. The paper describes the activity of Z212, a novel proprietary small organic compound that acts to modulate Nav1.7 and Nav1.8 sodium channels and to reduce neuropathic pain by targeting the hyper-excitability associated with chronic pain signaling pathways.
More than half of all retired people aged 65 and over report sleeping at least 7.5 hours per night, and between the hours of 11 p.m. and 7:30 a.m., contrary to commonly held assumptions that most elderly go to bed early and have trouble sleeping through the night, according to a study by researchers at the University of Pittsburgh's Sleep and Chronobiology Center (SCC) and University Center for Social and Urban Research (UCSUR).
Merck, known as MSD outside the United States and Canada, and BGI, the world's largest genomics center, announced today that they have established a collaboration to focus on the discovery and development of biomarkers and genomic technologies.
ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announces that the US Food and Drug Administration (FDA) has notified the Company that its new biologic license application (BLA) for ocriplasmin intravitreal injection will be discussed at the Dermatologic and Ophthalmic Drugs Advisory Committee scheduled for July 26, 2012.
A study published in the journal "Cytogenetic and Genome Research" shows that exposure to Agent Orange, and other defoliants, has led to genetic disturbance in New Zealand Vietnam War veterans which continues to persist decades after their service.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Farzad Saleh, DPM 106 Fiesta Dr, Stephenson, VA 22656-1876 Ph: (240) 285-4270 | Dr Farzad Saleh, DPM 6130 Oxon Hill Rd Ste 305, Oxon Hill, MD 20745-3168 Ph: (301) 567-5005 |
News Archive
Zalicus Inc. today announced the publication of preclinical data in the journal PAIN. The paper describes the activity of Z212, a novel proprietary small organic compound that acts to modulate Nav1.7 and Nav1.8 sodium channels and to reduce neuropathic pain by targeting the hyper-excitability associated with chronic pain signaling pathways.
More than half of all retired people aged 65 and over report sleeping at least 7.5 hours per night, and between the hours of 11 p.m. and 7:30 a.m., contrary to commonly held assumptions that most elderly go to bed early and have trouble sleeping through the night, according to a study by researchers at the University of Pittsburgh's Sleep and Chronobiology Center (SCC) and University Center for Social and Urban Research (UCSUR).
Merck, known as MSD outside the United States and Canada, and BGI, the world's largest genomics center, announced today that they have established a collaboration to focus on the discovery and development of biomarkers and genomic technologies.
ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announces that the US Food and Drug Administration (FDA) has notified the Company that its new biologic license application (BLA) for ocriplasmin intravitreal injection will be discussed at the Dermatologic and Ophthalmic Drugs Advisory Committee scheduled for July 26, 2012.
A study published in the journal "Cytogenetic and Genome Research" shows that exposure to Agent Orange, and other defoliants, has led to genetic disturbance in New Zealand Vietnam War veterans which continues to persist decades after their service.
› Verified 5 days ago
Dr. Chris Obiarinze, Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 6130 Oxon Hill Rd Ste 305, Oxon Hill, MD 20745 Phone: 301-567-5005 | |
Charles Hu, Podiatrist Medicare: Medicare Enrolled Practice Location: 6130 Oxon Hill Rd Ste 305, Oxon Hill, MD 20745 Phone: 301-567-5005 | |
Dr. Leonard Wisotsky, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 6188 Oxon Hill Rd, Ste 804, Oxon Hill, MD 20745 Phone: 301-567-5005 Fax: 301-839-5677 | |
Podiatry Health & Wellness Care Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 6710 Oxon Hill Rd Ste 210, Oxon Hill, MD 20745 Phone: 202-670-4546 | |
Hufsa Hussan, Podiatrist Medicare: Accepting Medicare Assignments Practice Location: Progressive Feet Llc, 6130 Oxon Hill Rd Ste 305, Oxon Hill, MD 20745 Phone: 301-567-5005 | |
Dr. Taunna Jones, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 6710 Oxon Hill Rd Ste 210, Oxon Hill, MD 20745 Phone: 202-670-4546 |